JW Shinyak Corp

JW Shinyak Corp maintains a capital structure with a debt-to-equity ratio of 1.74, indicating a relatively high reliance on debt financing. The company holds 20.31 billion KRW in cash and equivalents, but this is offset by 31.35 billion KRW in long-term debt, resulting in a net cash position of -11.04 billion KRW. Despite a current ratio of 1.01, the company's liquidity is assessed as medium, suggesting potential short-term financial constraints.

Profitability metrics show a return on equity (ROE) of 9.26% and a return on assets (ROA) of 2.52%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The operating margin is 11.91%, and the net profit margin is 7.01%, both of which are in line with the industry median.

The company's revenue is concentrated in a single geographic market, South Korea, with no disclosed international operations. This lack of geographic diversification increases exposure to local economic and regulatory risks. The company operates in a single business segment, with no material diversification across product lines or therapeutic areas.

Looking ahead, the company is projected to see a 1.2% year-over-year decline in revenue for the current fiscal year, with a 0.8% decline expected in the following year. This suggests a modest contraction in the near term, driven by market saturation and competitive pressures in the domestic pharmaceutical sector.

The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position and high debt-to-equity ratio contribute to its liquidity concerns. No significant dilution events are expected in the near term, and the company has not issued new shares recently.

Recent financial filings and transcripts indicate that the company is facing challenges in maintaining consistent earnings. The latest actual EPS was reported at -352.74 KRW, reflecting a decline in profitability. Management has not disclosed specific strategies to address this decline, and there are no material new product launches or partnerships announced in the recent filings.

Net income surged 141.9% year-over-year to 15.7 billion KRW, signaling a robust recovery in profitability.

Free cash flow increased 143.7% to 15.8 billion KRW, providing substantial liquidity for future investments.

Net margin of 7.0% remains above the 3.9% industry median, supporting consistent bottom-line performance.

Debt-to-equity ratio of 1.74 falls in the bottom quartile, indicating significantly higher leverage than peers.

Cash conversion of -0.70 ranks in the bottom quartile, suggesting poor efficiency in generating cash from earnings.

Long-term debt increased to 3.4 billion KRW in FY0, reversing previous deleveraging trends and increasing financial risk.

Medium liquidity and credit risk flags suggest potential challenges in meeting short-term obligations or borrowing costs.

Revenue KRW 93.01B, −10,8% YoY; Operating income +128,2% YoY.

• ▍Revenue KRW 93.01B, −10,8% YoY
• ▍Operating income +128,2% YoY
• ▍Net income +113,6% YoY
• ▍Free cash flow +115,3% YoY
• ▍Net margin 5.5%